15 years’ experience with biological therapy of inflammatory rheumatic diseases in Czech national register ATTRA
Authors:
Karel Pavelka; Liliana Šedová; Karel Hejduk; Ladislav Dušek
Authors‘ workplace:
Institut biostatistiky a analýz MU
; Revmatologický ústav
Published in:
Čas. Lék. čes. 2016; 155: 285-293
Category:
Original Article
Overview
The publication is summarizing application of biological DMARDs in autoimmune inflammatory rheumatic diseases.
Up to now conventional therapy, which for example in rheumatoid arthritis was application of methotrexate (MTx) in combination with glucocorticoids, was effective, but the remission as a target was achieved in small proportion of patients and also there was little effect on structural progression of diseases. Biological therapy was great advance because response was achieved in ¾ patients who failed MTx. At present time 8 biological drugs are available. 5 are inhibitors of TNFα and 3 have different move of action. In psoriatic arthritis are beside TNF blockers available blocker of IL 17 (secukinumab, ustekinumab, apremilast). For ankylosing spondylitis is registered secukinumab.
Anti-TNF therapy is relative safe but rarely serious adverse events can occur. The most important are serious infections, opportunistic infections and tuberculosis. Other adverse event includes allergic reactions and local intolerance. Increase incidence of lymphomas was not confirmed. There is probably minimal increased risk of skin melanoma and non-melanoma tumors. Benefit/risk ratio is still very positive.
National registry of biological therapy ATTRA was founded 15 years ago and includes patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis. In June 2016 over all 6800 patients with those diagnoses was included and actually 5194 have been treated. In registry patients are regularly followed for activity, efficacy of the drug and other events. Results of registry are sent payers for evaluations of pharmacologic parameters.
Keywords:
biological therapy, registry, inflammatory rheumatic diseases
Sources
1. Pincus T, Callahan LF, Sale WG et al. Severe functional declines, work disability and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864–872.
2. Lundkvist J, Kasteng F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008; 8(Suppl: 2): S49–S60.
3. Szabo SM, Levy AR, Sao SR et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011; 63: 3294–3304.
4. Nam J, Ramiro S, Gaujox-Viala C et al. Efficacy of biological disease modifying antirheumatic drugs: A systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 516–528.
5. Zochling J, van der Heijde D, Vargas RB et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442–452.
6. Pavelka K, Gatterová J, Tegzová D et al. Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment. Clin Exp Rheumatol 2007; 25: 540–545.
7. Wolfe F, Boers M, Felson D. Remission in rheumatoid arthritis, physician and patient perspectives. J Rheumatol 2009; 36: 930–933.
8. Pavelka K, Vencovský J. Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. Česká revmatologie 2010; 18: 182–191.
9. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73(3): 492–509.
10. Šedová L, Štolfa J, Horák P, Pavelka K. Doporučení České revmatologické společnosti pro monitorování bezpečnosti léčby revmatoidní artritidy. Česká revmatologie 2009; 17(1): 4–15.
11. Závada J, Uher M, Hejduk K et al. Zdravím podmíněná kvalita života u pacientů s revmatoidní artritidou v průběhu prvního roku anti-TNF léčby. Česká revmatologie 2013; 21(3): 123–130.
12. Pavelka K, Gatterová J, Vencovský L et al. Rentgenová progrese revmatoidní artritidy v běžné klinické praxi – výsledky z českého registru ATTRA. Rheumatologia 2009; 23(1): 7–11.
13. Pavelka K, Chroust k, Němec P. Faktory ovlivňující účinnost anti-TNF terapie v klinické praxi: zkušenosti z národního registru ATTRA. Česká revmatologie 2014; 22(4): 115–123.
14. Pavelka K, Hejduk K, Mann H. Jaké jsou prediktivní faktory odpovědi na léčbu tocilizumabem v běžné klinické praxi? Zkušenosti z Českého národního registru ATTRA. Česká revmatologie 2013; 21(3): 132–139.
15. Horák P, Skácelová M, Hejduk K. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic – data from the ATTRA registry. Clin Rheumatol 2013; 32: 1451–1458.
16. Chatzidionysiu K, Lie E, Nasonov E et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011; 70: 1575–1580.
17. Chatzidionysiu K, Lie E, Nasonov E et al. Effectiveness of disease- modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 2012; 71: 374–377.
18. Šléglová O, Burešová L, Vencovský J, Pavelka K. Výskyt infekcí při léčbě antagonisty TNF alfa v registru ATTRA. Česká revmatologie 2011; 19(2): 86–91.
19. Pavelka K, Fojtíková M, Hejduk K. Efficacy of the first and subsequent courses of anti-TNF therapy in patients with ankylosing spondylitis – results from the Czech National Registr ATTRA. Rheumatologia 2012; 50(4): 294–306.
20. Závada J, Uher M, Sisol K et al. A tailored approach to reduce dose of anti TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann Rheum Dis 2016; 75(1): 96–102.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Differential diagnosis of monoarthritis
- Hand osteoarthritis
- Raynaud's phenomenon
- Immune mediated necrotizing myopathy associated with statin treatment